{"filings":[{"id":721808,"accession_number":"0001104659-26-067474","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2026-05-28T20:05:29+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BrainStorm appoints former FDA official Peter Pitts to Board ahead of ALS trial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Peter Pitts, former FDA Associate Commissioner, to the Board effective May 25, 2026.","Pitts granted option for 150,000 shares; half vested immediately, half vest in six months.","Company preparing to initiate Phase 3b ENDURANCE trial for NurOwn in ALS under FDA Special Protocol Assessment.","Board expanded from seven to eight directors; Pitts determined independent under SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472681,"accession_number":"0001104659-26-062766","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2026-05-15T21:00:31+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.","Cash, equivalents, and restricted cash $0.2M at March 31, 2026, down from $0.3M at Dec 31, 2025.","R&D expense $0.8M (down from $1.3M); G&A expense $1.3M (down from $1.8M).","Planning Phase 3b ENDURANCE trial of NurOwn for ALS, targeting ~200 patients; BLA submission planned after Part A.","Raised $2M via two private placements in Feb 2026; stockholders' deficit $11M; accounts payable $7.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101653,"accession_number":"0001104659-26-037760","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm reports FY2025 net loss $10.3M; secures $2M post-year-end for Phase 3b","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, restricted cash $0.3M at Dec 31, 2025; raised $2M in Feb 2026 private placements.","Net loss $10.3M ($1.11/share) vs $11.6M ($2.31/share) in 2024; R&D spend $4.2M, G&A $5.8M.","FDA cleared Phase 3b ENDURANCE study of NurOwn for ALS; ~200 participants, SPA and CMC aligned.","Expanded Access Program: 5/10 patients alive, mean survival ~84 months; all 10 exceeded 5-year survival.","Company highlights $2M strategic financing as catalyst for share re-rating and cash runway for operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101652,"accession_number":"0001104659-26-021613","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics raises $1M in private placement, increases share pool by 5.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered securities purchase agreement for $1M private placement; initial closing of $125K at $0.60/share.","Investor may purchase up to $875K in additional closings through Sept 25, 2026, with common warrants at $1.00/share.","Board approved 5.5M share increase in 2014 stock incentive plan pool, now totaling ~8.4M shares.","Proceeds from private placement to be used for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101651,"accession_number":"0001104659-26-015262","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics raises $1M in private placement at $0.60 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Securities Purchase Agreement for $1M total, closings of $500k each on Feb 9, 2026 and ~30 days later.","Investor receives common stock or pre-funded warrants at $0.60 and common warrants for 120% of shares at $1.00 exercise price.","First closing occurred on February 9, 2026; second closing subject to conditions.","Net proceeds for working capital; registration statement to be filed within 45 days.","Issuance exempt under Section 4(a)(2) and Regulation D; OTCQB ticker BCLI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101650,"accession_number":"0001104659-26-002494","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BCLI issues three convertible notes to institutional investors, total ~$329K principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Vanquish Funding: $94.3K note (12% OID), convertible at 65% of lowest trading price upon default, matures Oct 2026.","Quick Capital: $94.9K note (10% OID), convertible at 75% of lowest trading price upon default, matures Jan 2027.","Auctus Fund: $140K note (12% OID), convertible at 65% of lowest trading price after 6 months or upon default, matures 12 months.","Notes include default penalties of 150% of outstanding, cross-default provisions, and beneficial ownership limitations at 4.99%.","Proceeds used for general working capital; issuance exempt under Section 4(a)(2) and Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117986,"accession_number":"0001104659-25-112682","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics issues $143,750 note to Labrys Fund II, reports Q3 2025 results","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered securities purchase agreement with Labrys Fund II for a promissory note of $143,750, including $18,750 original issue discount, receiving net proceeds of $121,500.","Note requires six payments of $22,589 starting May 2026, matures November 10, 2026, and is convertible at 25% discount to lowest trading price over 20 days, subject to 4.99% ownership cap.","Q3 2025 net loss was $2.1 million ($0.19 per share); cash and equivalents were $0.23 million as of September 30, 2025.","R&D expenses were $0.9 million and G&A expenses were $1.1 million, both down from prior year quarter.","FDA cleared Phase 3b ENDURANCE trial of NurOwn for ALS; a Citizen Petition was filed by ALS community representatives seeking renewed regulatory review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117985,"accession_number":"0001104659-25-107833","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics issues $182,400 convertible note to Vanquish Funding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $182,400 promissory note (incl. $22,400 OID) to Vanquish Funding; net proceeds ~$155,000 after $5,000 fees.","Note bears 12% interest (22% if unpaid), matures August 30, 2026; convertible at 35% discount to lowest 10-day trading price.","Additional tranches up to $2M available over 12 months subject to further agreement with Vanquish.","Conversion shares subject to 4.99% beneficial ownership cap; issued under Section 4(a)(2) exemption.","Proceeds will be used for general working capital purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134444,"accession_number":"0001104659-25-078116","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm Q2 net loss $2.9M; FDA clears Phase 3b NurOwn trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents total $1.03M as of June 30, 2025.","Net loss per share improved to $0.34 from $0.60 YoY.","G&A expenses fell to $1.4M from $2.1M; R&D rose to $1.1M from $0.9M.","FDA cleared Phase 3b ENDURANCE trial targeting ~200 ALS patients.","Signed LOI with CDMO Minaris for NurOwn manufacturing for the trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134443,"accession_number":"0001104659-25-068709","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).","Nasdaq trading suspended at open on July 18, 2025; company received notice on July 16.","Shares approved for OTCQB quotation under same symbol BCLI starting July 18.","CEO states delisting does not alter mission; focus on NurOwn Phase 3b trial under SPA with FDA.","Company confirms no impact on business operations or ongoing R&D efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151284,"accession_number":"0001104659-25-062595","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Brainstorm Cell shareholders approve 2M share increase in equity plan pool","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing the shared pool under the 2014 plans by 2M shares, to 2,906,666 shares.","Vote: 758,668 for, 362,809 against, 2,556,446 broker non-votes for the plan amendments.","All seven director nominees elected; Dr. Stacy Lindborg received the most votes (1,055,967 for).","Ratification of Brightman Almagor Zohar & Co. as FY2025 auditor approved (3,346,891 for).","Approval of warrant share issuance under Nasdaq Rule 5635(d) passed (874,965 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151283,"accession_number":"0001104659-25-059900","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.","Median survival in small cohort was 6.8 years; only death was elective euthanasia.","Company says data strengthens rationale for Phase 3b trial of NurOwn in ALS under FDA SPA.","CEO and CMO highlighted clinically meaningful observation in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151282,"accession_number":"0001104659-25-050441","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BrainStorm receives FDA clearance to initiate Phase 3b trial of NurOwn for ALS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Phase 3b trial under Special Protocol Assessment (SPA); endpoints agreed for future BLA.","Trial to enroll ~200 participants at academic centers; 24-week double-blind phase plus 24-week open-label extension.","Primary endpoint: change from baseline to week 24 on ALS Functional Rating Scale-Revised (ALSFRS-R).","Company plans to activate sites in phases and secure funding via non-dilutive grants.","Investor call and webcast scheduled for May 19 at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151281,"accession_number":"0001104659-25-049581","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.","Cash, equivalents restricted cash $1.8M at March 31, 2025; R&D $1.3M, G&A $1.8M.","Submitted IND amendment for Phase 3b NurOwn trial (ENDURANCE) targeting ~200 early ALS patients with SPA.","Trial listed on ClinicalTrials.gov (NCT06973629) with 15 clinical sites; data at ISCT and ALS Summit.","Conference call rescheduled to May 19, 2025 at 8:30 AM ET."],"consensus_eps_estimate":-0.9894,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151280,"accession_number":"0001104659-25-036851","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.03","5.08","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics amends bylaws to reduce quorum to 1/3; sets 2025 annual meeting for June 25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reducing stockholder quorum from majority to one-third of outstanding shares.","2025 Annual Meeting to be held virtually on June 25, 2025 at 10:00 a.m. ET.","Record date for voting is May 7, 2025; shareholder proposals due by same date.","Director nominations under universal proxy rules must be received by May 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170164,"accession_number":"0001104659-25-029608","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Brainstorm Cell reports FY2024 net loss $11.6M; cash only $0.4M; raises $1.64M via warrant inducement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.6M ($2.31 per share) improved from $17.2M loss ($6.00 per share) in 2023.","Cash and short-term deposits fell to $0.4M at year-end from $1.5M; company entered warrant inducement to raise ~$1.64M on April 1.","R&D spending reduced to $4.7M from $10.7M; G&A also cut to $7.0M from $10.7M.","Phase 3b trial of NurOwn for ALS proceeding with FDA SPA; partnership with Pluri for manufacturing."],"consensus_eps_estimate":-0.9894,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170163,"accession_number":"0001104659-25-029580","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics enters warrant inducement deal for ~$1.64M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder to exercise existing warrants for 1,381,383 shares; new warrants at 200% of exercised shares.","New warrants have $1.19 exercise price, exercisable after stockholder approval, 5-year term.","Gross proceeds ~$1.64M; net proceeds for working capital and general corporate purposes.","Maxim Group acting as inducement agent with 6% cash fee and $12,500 expenses.","Company must seek stockholder approval within 90 days; resale registration statement to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170162,"accession_number":"0001104659-25-028529","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq panel grants Brainstorm Cell Therapeutics extension to June 30, 2025 to regain listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.","Company plans to meet $2.5M minimum stockholders' equity requirement as alternative to MVLS compliance.","Extension conditioned on demonstrating compliance with Nasdaq Listing Rule 5550 and progress in capital raising.","Company cannot assure success in raising capital or satisfying equity requirement by the extension date.","Plan presented at February 25, 2025 hearing; capital raising activities are a key component."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170161,"accession_number":"0001104659-25-004953","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BCLI fails to regain Nasdaq MVLS compliance; delisting stayed pending Feb 25 hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company previously failed to meet Nasdaq's minimum market value of listed securities requirement by Jan 14, 2025.","On Jan 21, 2025, submitted a hearing request to appeal the Staff's delisting determination.","Nasdaq confirmed hearing on Feb 25, 2025; delisting action is stayed pending final Panel decision.","Company will present plan to regain compliance and sustain long-term listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170160,"accession_number":"0001104659-25-003777","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Brainstorm Cell receives Nasdaq delisting notice for failure to meet MVLS minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BCLI on Jan 15, 2025 that it failed to regain compliance with the $35M MVLS requirement by the Jan 14 deadline.","Unless BCLI appeals by Jan 22, 2025, its common stock will be delisted from the Nasdaq Capital Market at open on Jan 24, 2025.","Company intends to appeal the delisting determination, but no assurance of success or continued listing.","BCLI previously received a 180-day cure period on July 18, 2024 to meet the MVLS rule (Nasdaq 5550(b)(2))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187173,"accession_number":"0001104659-24-119041","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm Q3 net loss widens to $2.7M, cash at $0.35M; advancing NurOwn Phase 3b trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, restricted cash only $0.35M as of Sept 30, 2024; net loss $2.7M ($0.51/shr) vs $1.2M ($0.45) YoY.","R&D expenses fell to $1M from $3.3M; G&A to $2M from $2.7M.","Signed MOU with Pluri Inc. to manufacture NurOwn for planned Phase 3b ALS trial enrolling ~200 participants.","Phase 3b: 24-week placebo-controlled part (Part A) then 24-week open-label (Part B); primary endpoint: ALSFRS-R change at week 24.","Expanded Access data showed median survival 46.6 vs 41.1 months (p=0.0379) and consistent reductions in neurofilament light."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187172,"accession_number":"0001104659-24-112442","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"BrainStorm regains Nasdaq minimum bid price compliance; listing continues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice of compliance on Oct 29, 2024; common stock continues on Nasdaq Capital Market.","Effected 1-for-15 reverse stock split on Sep 30, 2024 to regain compliance.","Stock closed above $1.00 for ten consecutive trading days as of Oct 15, 2024.","Previously faced delisting; Nasdaq hearing panel granted temporary exception until Oct 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187171,"accession_number":"0001104659-24-104920","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["3.01","5.03","3.03","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:15 ratio effective 11:59 p.m. ET on September 30, 2024.","Trading on split-adjusted basis began October 1, 2024; new CUSIP 10501E300.","Authorized shares unchanged at 250 million; fractional shares paid in cash based on closing price.","Reverse split also applies to warrants, options, and RSUs with proportionate adjustments.","Split intended to increase per share bid price above $1.00 to satisfy Nasdaq continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187170,"accession_number":"0001104659-24-104667","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Brainstorm Cell publishes corporate presentation; no material new facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company released a corporate presentation on October 1, 2024, furnished as Exhibit 99.1.","Presentation will be available on the investor relations section of the company's website.","Filing excerpt does not contain specific financial or operational details; content of slide not fully provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203684,"accession_number":"0001104659-24-103157","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics announces 1-for-15 reverse stock split effective Sept 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-15 reverse stock split on Sept 23, 2024; stockholders authorized at Sept 16 meeting.","Reverse split effective at 11:59 p.m. ET on Sept 30, 2024; trading on split-adjusted basis Oct 1 under BCLI.","No fractional shares issued; cash in lieu based on closing price prior to effective time.","New CUSIP number 10501E 300; par value unchanged at $0.00005 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203683,"accession_number":"0001104659-24-100239","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Brainstorm Cell shareholders OK 150M authorized share increase, reverse split, equity plan boost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increasing authorized common shares from 100M to 250M.","Board authorized to effect reverse stock split of 1:5 to 1:15 at any time before Sept 16, 2025.","Equity plan share pool increased by 8M shares to 13.6M; each plan extended to 2034.","All seven director nominees elected; Brightman Almagor Zohar & Co. ratified as auditor.","Advisory vote on executive compensation approved with a 3-year frequency for future votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203682,"accession_number":"0001104659-24-089295","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm Q2 net loss narrows to $2.5M; FDA alignment on NurOwn Phase 3b trial CMC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2024 was $2.5M ($0.04/sh), compared to $5.3M ($0.13/sh) in Q2 2023.","Cash, cash equivalents, and restricted cash were $3.65M as of June 30, 2024.","Reached FDA alignment on CMC aspects for Phase 3b NurOwn trial in ALS, following SPA agreement in April.","Appointed Hartoun Hartounian Ph.D. as EVP/COO and promoted Dr. Bob Dagher to EVP/CMO.","Completed registered direct offering raising $4.0M gross proceeds from single institutional investor."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203681,"accession_number":"0001104659-24-083959","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics sets 2024 annual meeting for Sep 16, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting to be held virtually on Sep 16, 2024 at 10:00 a.m. Eastern time.","Record date for voting is August 12, 2024.","Stockholder proposals for proxy inclusion due by August 12, 2024.","Director nominations under universal proxy rules due by August 9, 2024.","Meeting more than 30 days later than 2023 meeting; new deadlines supersede prior ones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203680,"accession_number":"0001104659-24-081162","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Nasdaq warns Brainstorm Cell Therapeutics of MVLS deficiency; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on July 18, 2024 for MVLS below $35M minimum.","Company has until January 14, 2025 to regain compliance by closing at $35M or more for 10 consecutive business days.","If not compliant by deadline, Nasdaq may delist BCLI common stock; company may appeal.","No immediate impact on trading; BCLI continues to trade on Nasdaq Capital Market.","Company intends to monitor and take reasonable measures to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220222,"accession_number":"0001104659-24-075995","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BrainStorm Cell Therapeutics raises $4.0M in registered direct offering and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M from sale of 11.1M shares or pre-funded warrants at $0.36/share.","Private placement of warrants to buy 16.7M shares at $0.3912, exercisable after 6 months, 5-year term.","Existing warrants for 4.05M shares amended: exercise price cut to $0.3912, expiry extended to 2029.","Offering expected June 28, 2024; Maxim Group as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220221,"accession_number":"0001104659-24-075146","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BrainStorm reaches alignment with FDA on CMC for NurOwn Phase 3b ALS trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA alignment on Chemistry, Manufacturing, and Controls (CMC) for Phase 3b trial of NurOwn for ALS.","Follows April 2024 Special Protocol Assessment (SPA) agreement de-risking trial design and endpoints.","CEO Chaim Lebovits says all previously outstanding CMC questions resolved.","Company moves forward with pivotal Phase 3b trial aiming for NurOwn approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220220,"accession_number":"0001104659-24-073484","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.","Base salary $450k/year; option for 60k shares and 30k restricted stock grant.","Eligible for annual cash bonus up to 35% of base salary and $10k signing bonus.","Previously founded BioCentriq, a CDMO acquired for $73M by GC Holdings.","Appointment supports operational readiness for NurOwn® Phase 3b ALS study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220219,"accession_number":"0001104659-24-068007","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Brainstorm Cell Therapeutics temporary exception until Oct 21 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received delisting notice on May 1 for failing $1 minimum bid price; appealed on May 2.","Nasdaq granted temporary exception until Oct 21, 2024; must comply by then or face delisting.","If not compliant by mid-August 2024, must execute reverse stock split no later than Oct 7, 2024.","No assurance reverse split will achieve compliance; delisting risk persists if deadline missed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220218,"accession_number":"0001104659-24-056971","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Brainstorm Cell receives Nasdaq delisting notice; files appeal to stay trading","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Staff Letter on May 1, 2024 for failing to meet $1.00 minimum bid price by April 29, 2024.","Submitted hearing request to Nasdaq Hearings Panel on May 2, 2024 to appeal delisting determination.","Suspension and Form 25-NSE stayed pending final Panel decision; trading continues under BCLI.","No assurance that Panel will grant an exception or that compliance will be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220217,"accession_number":"0001104659-24-047974","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"BrainStorm CEO Steps Down, CMO Promoted; Phase 3b Trial for NurOwn Planned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Co-CEO Stacy Lindborg resigns effective May 9, 2024, but will join the Board of Directors.","Dr. Bob Dagher promoted from Chief Development Officer to Executive VP and Chief Medical Officer.","Company plans registrational Phase 3b trial for NurOwn (ALS) under FDA Special Protocol Assessment.","Separation agreement includes $300,000 lump sum payment and continued vesting of certain equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220216,"accession_number":"0001104659-24-046001","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Brainstorm Cell regains Nasdaq minimum market value compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received Nasdaq notification on April 10, 2024 that it regained compliance with Listing Rule 5550(b)(2).","Market value of listed securities was >= $35M for 11 consecutive business days (Mar 22 – Apr 9, 2024).","Previous deficiency notice received November 6, 2023; matter now closed.","Continued listing on Nasdaq Capital Market is no longer in jeopardy.","Press release issued April 11, 2024 confirms compliance reinstatement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220215,"accession_number":"0001104659-24-044928","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BrainStorm announces FDA SPA agreement for Phase 3b trial of NurOwn in ALS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on Phase 3b trial design under Special Protocol Assessment (SPA) for NurOwn in ALS.","Phase 3b trial (BCT-006-US) to enroll ~200 patients, double-blind placebo-controlled Part A (24 weeks) then open-label Part B.","Primary endpoint: change in ALSFRS-R total score at Week 24; CAFS to account for mortality.","Company expects trial commencement in 2024 after investigator and IRB approvals.","SPA validates protocol adequacy for supporting a future Biologics License Application (BLA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220214,"accession_number":"0001104659-24-042513","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Brainstorm Cell Therapeutics removes Leerink Partners as ATM selling agent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Distribution Agreement dated April 2, 2024 removes Leerink Partners as agent.","Raymond James remains as the sole agent under the existing $100M ATM equity program.","Original Distribution Agreement was entered August 9, 2021; no change to offering size or terms.","Company's common stock trades on Nasdaq under ticker BCLI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220213,"accession_number":"0001104659-24-041549","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Brainstorm Cell reports FY2023 net loss of $17.2M; cash drops to $1.45M; awaits FDA SPA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.2M ($0.40/share) vs $24.3M ($0.66) in 2022; no revenue (pre-revenue biotech).","Cash and equivalents $1.45M at Dec 31, 2023, down from $3M in 2022; raises going-concern risk.","R&D expenses fell to $10.8M from $14M; headcount reduced ~30% in October 2023 strategic realignment.","Submitted SPA request to FDA in Feb 2024 for Phase 3b trial of NurOwn in ALS; awaiting 45-day review.","Withdrew BLA for NurOwn in Oct 2023 after FDA advisory committee voted against effectiveness evidence."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257427,"accession_number":"0001104659-23-127772","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"BrainStorm plans Phase 3b NurOwn trial, SPA submission in Feb 2024 after ADCOM setback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Chaim Lebovits letter outlines Phase 3b trial as most expedient path to FDA approval for NurOwn ALS therapy.","Company expects to submit clinical protocol, SAP, and SPA request to FDA in February 2024; FDA response within 45 days.","Type A meeting held Dec 6, 2023; FDA engaged and recognized unmet need in ALS, says BrainStorm.","Funding strategies being explored; company aims to boost stock price by April to maintain NASDAQ listing, preferring organic support over reverse split.","Dr. Menghisteab Bairu appointed to Audit Committee replacing Dr. June S. Almenoff, effective Dec 18, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257426,"accession_number":"0001104659-23-120495","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BrainStorm announces FDA meeting on Dec 6 to discuss SPA for NurOwn Phase 3b in ALS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted in-person meeting scheduled for December 6, 2023, to discuss NurOwn's regulatory path in ALS.","BrainStorm plans to seek Special Protocol Assessment (SPA) agreement for a confirmatory Phase 3b trial.","Company aims to align with FDA on re-submission requirements for Biologics License Application (BLA).","CEO states SPA agreement could de-risk program and position company for success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257425,"accession_number":"0001104659-23-117678","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Brainstorm reports Q3 net loss $1.2M; withdraws NurOwn BLA for ALS, cuts 30% headcount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Withdrew BLA for NurOwn in ALS after FDA advisory committee vote; FDA invites expedited meeting for path forward.","Strategic realignment reduces headcount ~30%, targets cutting total resource consumption by half.","Cash, equivalents, and short-term deposits at $1.4M as of Sep 30, 2023, down from $3M at Dec 31, 2022.","Net loss for Q3 2023 was $1.2M ($0.03 per share) vs. $6.9M ($0.19 per share) in Q3 2022.","Raised ~$7.5M gross in July 2023 registered direct offering with a single institutional investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257424,"accession_number":"0001104659-23-116254","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Brainstorm Cell Nasdaq delisting risk: MVLS below $35M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Nov 6, 2023 for MVLS below $35M required for continued listing.","Has 180 calendar days, until May 6, 2024, to regain compliance; must close at $35M+ for 10 consecutive days.","Common stock continues trading under symbol BCLI on Nasdaq Capital Market during compliance period.","Company intends to take reasonable measures to regain compliance but no assurance of success.","If not compliant by May 6, 2024, Nasdaq may delist; appeal possible but uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257423,"accession_number":"0001104659-23-114279","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Brainstorm Cell receives Nasdaq bid price deficiency notice; has until April 29, 2024 to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BCLI on Nov 1, 2023 of non-compliance with $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).","No immediate delisting; stock continues trading on Nasdaq Capital Market under symbol BCLI.","Company has 180 days, until April 29, 2024, to regain compliance by closing at or above $1.00 for 10 consecutive business days.","If not compliant by April 29, BCLI may qualify for an additional 180-day compliance period if other listing standards are met.","Company intends to monitor bid price and take reasonable measures, but there is no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257422,"accession_number":"0001104659-23-110945","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"BrainStorm cuts 30% headcount, CMO departs, plans NurOwn Phase 3b trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force of ~30% with estimated severance costs of $450k-$900k, substantially complete by end of 2023.","Dr. Kirk Taylor steps down as EVP and Chief Medical Officer effective October 18, 2023, not due to any disagreement.","Company plans double-blind, placebo-controlled Phase 3b U.S. trial for NurOwn in ALS with open-label extension.","Total resource consumption to be reduced by ~50% to fund ALS development; exploring capital raising options.","Positions critical to Phase 3b trial and regulatory submission retained; clean room operations streamlined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274771,"accession_number":"0001104659-23-090892","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BrainStorm Q2 net loss $5.3M; NurOwn ADCOM set for Sep 27, PDUFA Dec 8","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.3M ($0.13 per share) vs $7.0M in Q2 2022.","Cash $0.75M at June 30; raised $7.5M in July direct offering.","FDA ADCOM for NurOwn BLA scheduled Sep 27; PDUFA target Dec 8, 2023.","Appointed Dr. Bob Dagher as Chief Development Officer and Dr. Kirk Taylor as Chief Medical Officer.","Biomarker data from Phase 3 showed NurOwn lowered neurofilament light, a predictor of clinical benefit in ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274770,"accession_number":"0001104659-23-082342","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BrainStorm Cell Therapeutics announces $7.5M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,054,055 shares at $1.85 each, each with a warrant to purchase one share at $2.00 for five years.","Gross proceeds of ~$7.5M before placement agent fees and expenses.","Closing expected July 19, 2023; Maxim Group LLC is sole placement agent.","Offered under existing S-3 shelf registration statement (File No. 333-258640)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292091,"accession_number":"0001104659-23-072950","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BrainStorm appoints Nir Naor as Board member and Audit Committee chair; Taub resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Malcolm Taub resigned from Board effective June 15, 2023; decision not due to any disagreement with the Company.","Nir Naor elected to Board effective June 20, 2023, as new independent director, Audit Committee chair, and GNC Committee member.","Naor receives initial grant of 11,999 restricted shares plus annual stock option or restricted stock awards, vesting monthly over 12 months.","Naor has over 20 years of finance and biotech experience, including CFO of Arbor Pharmaceuticals and senior roles at UCB and AstraZeneca."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292090,"accession_number":"0001104659-23-068364","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA schedules advisory committee meeting for BrainStorm's NurOwn BLA on Sept 27, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Cellular, Tissue and Gene Therapies Advisory Committee to review NurOwn BLA for ALS on September 27, 2023.","PDUFA target action date set for December 8, 2023.","Company states confidence in data supporting regulatory approval and commitment to ALS community.","BrainStorm notes FDA regulatory flexibility and ongoing work with ALS experts on rigorous clinical study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292089,"accession_number":"0001104659-23-064177","cik":1137883,"company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Brainstorm Cell Therapeutics COO David Setboun resigns effective May 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Setboun, PhD, MBA, EVP and COO, notified resignation on May 18, 2023.","Resignation effective May 31, 2023; he is leaving to pursue another opportunity.","Dr. Setboun's decision was not due to any disagreement with the company's operations, policies, or practices.","BCLI has not announced a replacement for the COO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7834690.541318744,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-24T23:59:59+00:00|292089"}